Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention
-
Published:2022-09-22
Issue:3
Volume:11
Page:40-50
-
ISSN:2587-9537
-
Container-title:Complex Issues of Cardiovascular Diseases
-
language:
-
Short-container-title:Kompleks. probl. serdečno-sosud. zabol.
Author:
Nalesnik E. O.1ORCID, Repin A. N.1ORCID
Affiliation:
1. Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences (Tomsk NRMC)
Abstract
Highlights. The frequency of long-term fatal cardiovascular complications in patients with chronic coronary syndrome subjected to selective (non-emergency) percutaneous coronary interventions was estimated.Risk stratification model of long-term fatal cardiovascular complications in patients with chronic coronary syndrome subjected to selective percutaneous coronary interventions has been created.Aim. To determine the frequency of long-term fatal cardiovascular events (CVE) after elective percutaneous coronary interventions (PCI) and to develop a model for stratifying the risk of these events.Methods. 150 patients with chronic coronary syndrome and indications for endovascular myocardial revascularization were included in the research. After PCI the patients were observed on an outpatient basis for year. The frequency of fatal cardiovascular complications was estimated by telephone interview 6 years after the index intervention.Results. Survival in the study group after 6 years was 86.1%. Fatal CVEs were reported in 10.6% of patients. The following baseline variables were significant predictors of cardiovascular death included in the individual risk assessment model: NYHA functional class of chronic heart failure (odds ratio (OR) 0.06, 95% confidence interval (CI) 0.003-1.106), lean plasma glucose level (OR 0.07, 95% CI 0.12-0.43), atrial fibrillation (OR 43.1, 95% CI 2.01–922.01), as well as the value of creatinine in the blood one year after the intervention (OR 1.14, 95% CI 1.0–1.3) and glomerular filtration rate (CKD-EPI) (OR 1.4, 95% CI 1.09–1.81). The area under the curve (AUC) of the developed model was 0.976 [95% CI 0,000–1,000].Conclusion. The proposed risk stratification model of developing long-term fatal cardiovascular complications in patients with chronic coronary syndrome subjected to selective (non-emergency) PCI allows identifying patients with an unfavorable long-term (six-year) prognosis.
Subject
Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Rehabilitation,Emergency Medicine,Surgery
Reference22 articles.
1. Gheorghe A., Griffiths U., Murphy A., Legido-Quigley H., Lamptey P., Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018; 18: 975. Doi: 10.1186/s12889-018-5806-x 2. Zykov M.V., D’yachenko N.V., Trubnikova O.A., Erlih A.D., Kashtalap V.V., Barbarash O.L. Comorbidity and Gender of Patients at Risk of Hospital Mortality After Emergency Percutaneous Coronary Intervention. Kardiologiia. 2020; 60(9): 38–45. (In Russian) doi: 10.18087/cardio.2020.9.n1166 3. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrà U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D.R., Løchen M.L., Löllgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y., Tiberi M., van der Worp H.B., van Dis I., Verschuren W.M.M., Binno S.; ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37: 2315–2381. doi:10.1093/eurheartj/ehw106 4. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Ž., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M.M., Vlachopoulos C., Wood D.A., Zamorano J.L., Cooney M.T.; ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37: 2999–3058. doi:10.1093/eurheartj/ehw272 5. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713–1722. doi:10.1056/NEJMoa1615664
|
|